CADTH drug reimbursement recommendation : indication: treatment and control of bleeding episodes in adults (age ≥ 18) diagnosed with von Willebrand disease (VWD) and perioperative management of bleeding in adults (age ≥ 18) diagnosed with VWD. von Willebrand factor (Recombinant) (Vonvendi -- Takeda Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Von Willebrand disease.

Cost effectiveness.

Physical Description:

1 online resource (10 pages)

Edition:

Version: Final.

Place of Publication:

Ottawa : Canadian Agency for Drugs and Technologies in Health, 2021.

Summary:

The CADTH Canadian Plasma Protein Product Expert Committee (CPEC) recommends that von Willebrand factor (recombinant; rVWF) should be reimbursed for the treatment and control of bleeding episodes or perioperative management of bleeding in adults (aged ≥ 18) diagnosed with VWD only if the following conditions are met. Conditions for Reimbursement: Initiation criteria 1. Adult patients with severe non-type 3 and type 3 VWD defined as any of the following: 1.1. Type 1 (VWF:RCo < 20 IU/dL) 1.2. Type 2A (VWF:RCo < 20 IU/dL), Type 2B (diagnosed by genotype), Type 2N (FVIII:C < 10% and historically documented genetics), or Type 2M 1.3. Type 3 (VWF:Ag ≤ 3 IU/dL). Prescribing conditions 1. The patients must be under the care of a hematologist with experience in the diagnosis and management of VWD. Pricing conditions 1. The public payer cost for rVWF with concomitant rFVIII should not exceed the public payer cost of treatment with the least costly alternative treatment regimen for the management of VWD.

Notes:

Description based on publisher supplied metadata and other sources.